

Special Issue

Artificial Intelligence in Neurobiology and Neurologic Diseases

Message from the Guest Editors

Millions of people are affected by neurological disorders. Patients with this condition have lots of limitations impacting not just their life but also their caregivers. Early detection of the condition can be improved with the help of Artificial Intelligence (AI) based techniques. AI is having a disruptive and transformative effect on clinical medicine. For neurology and neurobiology, there have been increasing interests in developing models and tools to address the complex patterns of connectivity in brain tissue. This special issue focuses on current AI-driven approaches to clinical neuroscience and an assessment of the associated key methodological and ethical challenges. The fundamentals of AI in neurobiology and neurology, its applications and use cases in various areas of neurobiology and neurology and how AI-based algorithms can transform the management of neurological diseases will be favored. Research implications, novel methods involving deep learning models, AI-based neuroimaging using brain scans to detect neurological disease will be highlighted.

Guest Editors

Prof. Dr. Wu Qiu

Biomedical Engineering, Huazhong University of Science and Technology, Wuhan, China

Dr. Hulin Kuang

School of Computer Science and Engineering, Central South University, Changsha, China

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/137279

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).